
NovaBridge Biosciences (NBP) Stock Forecast & Price Target
NovaBridge Biosciences (NBP) Analyst Ratings
Bulls say
NovaBridge Biosciences is a biotechnology platform that combines business development and clinical research to identify and advance pharmaceutical assets. This innovative company has a robust pipeline, with three clinical stage programs, and their core product, givastomig, has the potential to be a game-changing treatment for gastric cancer and other gastrointestinal malignancies. Furthermore, their VIS101 asset has demonstrated a durability-first approach, with prolonged target suppression and potentially longer dosing intervals, which could be a key differentiator in the market. Overall, NovaBridge Biosciences has a strong outlook with upcoming catalysts and a promising pipeline, making it an attractive investment opportunity.
Bears say
NovaBridge Biosciences is making progress with their clinical and regulatory advances, but the company's overall potential is still not fully appreciated by investors. However, as discussions at AACR 2026 have highlighted, their lead asset givastomig is differentiated in gastric and gastroesophageal cancers and is expected to enter Phase 3 clinical trials soon. Questions remain regarding the patient population and dosing for this asset, as well as the viability of their subsidiary Visara's VEGF-A x ANG-2 tetravalent peptibody for nAMD, but the company's restructuring efforts and FDA endorsements build confidence in their ability to execute successful global clinical programs.
This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.
NovaBridge Biosciences (NBP) Analyst Forecast & Price Prediction
Start investing in NovaBridge Biosciences (NBP)
Order type
Buy in
Order amount
Est. shares
0 shares